SI1776349T1 - 2-amino-kinazolinski derivati, uporabni kot zaviralci beta-sekretaze (bace) - Google Patents

2-amino-kinazolinski derivati, uporabni kot zaviralci beta-sekretaze (bace)

Info

Publication number
SI1776349T1
SI1776349T1 SI200531177T SI200531177T SI1776349T1 SI 1776349 T1 SI1776349 T1 SI 1776349T1 SI 200531177 T SI200531177 T SI 200531177T SI 200531177 T SI200531177 T SI 200531177T SI 1776349 T1 SI1776349 T1 SI 1776349T1
Authority
SI
Slovenia
Prior art keywords
beta
bace
secretase
inhibitors
amino
Prior art date
Application number
SI200531177T
Other languages
English (en)
Inventor
Ellen Baxter
Francois Paul Bischoff
Robert Boyd
Mirielle Braeken
Steven Coats
Yifang Huang
Alfonzo Jordan
Chi Luo
Marc Hubert Mercken
Charles H Reynolds
Tina Morgan Ross
Brett A Tounge
Mark Schulz
Winter Hans Louis Jos De
Serge Maria Aloysius Pieters
Allen B Reitz
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SI1776349T1 publication Critical patent/SI1776349T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SI200531177T 2004-08-06 2005-08-08 2-amino-kinazolinski derivati, uporabni kot zaviralci beta-sekretaze (bace) SI1776349T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59981104P 2004-08-06 2004-08-06
EP05785256A EP1776349B1 (en) 2004-08-06 2005-08-08 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace)
PCT/US2005/028191 WO2006017836A2 (en) 2004-08-06 2005-08-08 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace)

Publications (1)

Publication Number Publication Date
SI1776349T1 true SI1776349T1 (sl) 2011-01-31

Family

ID=35564387

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531177T SI1776349T1 (sl) 2004-08-06 2005-08-08 2-amino-kinazolinski derivati, uporabni kot zaviralci beta-sekretaze (bace)

Country Status (15)

Country Link
US (1) US8436006B2 (sl)
EP (1) EP1776349B1 (sl)
JP (1) JP4884387B2 (sl)
CN (1) CN101035771A (sl)
AT (1) ATE483692T1 (sl)
CY (1) CY1111086T1 (sl)
DE (1) DE602005024004D1 (sl)
DK (1) DK1776349T3 (sl)
ES (1) ES2351667T3 (sl)
HR (1) HRP20100595T1 (sl)
PL (1) PL1776349T3 (sl)
PT (1) PT1776349E (sl)
RS (1) RS51630B (sl)
SI (1) SI1776349T1 (sl)
WO (1) WO2006017836A2 (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8426429B2 (en) * 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) * 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US7868000B2 (en) 2005-06-14 2011-01-11 Schering Corporation Aspartyl protease inhibitors
ES2436795T3 (es) 2005-06-14 2014-01-07 Merck Sharp & Dohme Corp. Inhibidores heterocíclicos de aspartil proteasa, preparación y uso de los mismos
ES2360957T3 (es) * 2005-10-25 2011-06-10 Janssen Pharmaceutica Nv Derivados de 2-amino-3,4-dihidro-pirido(3,4-d)-pirimidina utiles como inhibidores de la beta-secretasa (bace).
US7776882B2 (en) * 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7868022B2 (en) 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
WO2007092839A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
AR061264A1 (es) 2006-06-12 2008-08-13 Schering Corp Inhibidores de aspartil-proteasas derivados de pirimidina, composiciones farmaceuticas que los contienen y usos para tratar enfermedades cognitivas o neurodegenerativas, y como inhibidores del virus vih.
US8093254B2 (en) 2006-12-12 2012-01-10 Schering Corporation Aspartyl protease inhibitors
US8222264B2 (en) 2007-07-06 2012-07-17 Boehringer Ingelheim International Gmbh Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
KR20100059919A (ko) * 2007-09-24 2010-06-04 코멘티스, 인코포레이티드 치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물
EP2219445A4 (en) * 2007-11-09 2013-05-29 Univ Tennessee Res Foundation INFLAMMATORY CHINIC ACID DERIVATIVES FOR ORAL ADMINISTRATION
BRPI0906625A2 (pt) * 2008-01-28 2015-07-14 Janssen Pharmaceutica Nv Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
AU2009209147B2 (en) * 2008-01-29 2013-03-14 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (BACE)
JP2011518225A (ja) 2008-04-22 2011-06-23 シェーリング コーポレイション Ｂａｃｅ−１阻害剤としてのフェニル置換２−イミノ−３−メチルピロロピリミジノン化合物、組成物、およびそれらの使用
WO2010042796A1 (en) * 2008-10-10 2010-04-15 Purdue Research Foundation Compounds for treatment of alzheimer's disease
EP2376083A4 (en) * 2008-11-20 2012-06-20 Purdue Research Foundation CHINAZOLIN INHIBITORS OF BACE 1 AND METHOD OF USE
US8859590B2 (en) 2008-12-05 2014-10-14 Purdue Research Foundation Inhibitors of BACE1 and methods for treating Alzheimer's disease
US9296698B2 (en) 2009-11-23 2016-03-29 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
RU2013150349A (ru) * 2011-04-13 2015-05-20 Мерк Шарп И Доум Корп. 5-замещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов васе, содержащие их композиции и их применение
CN103596939A (zh) * 2011-04-13 2014-02-19 默沙东公司 作为bace抑制剂的5-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其应用
WO2013148130A1 (en) * 2012-03-29 2013-10-03 Oklahoma Medical Research Foundation Inhibition of memapsin 1 cleavage in the treatment of diabetes
CA2902080A1 (en) 2013-02-25 2014-08-28 Merck Patent Gmbh 2-amino-3,4-dihydroquinazoline derivatives and the use thereof as cathepsin d inhibitors
US11701334B2 (en) 2018-01-10 2023-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138595A (en) * 1962-12-03 1964-06-23 American Home Prod Nu-(cycloalkyl)-pteridinecarboxamides
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3983120A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3988340A (en) * 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
US4001237A (en) * 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
CA1131631A (en) 1979-06-20 1982-09-14 Madhukar S. Chodnekar Quinazoline derivatives and pharmaceutical preparations
ZA803535B (en) 1979-06-20 1981-06-24 Hoffmann La Roche Novel quinazoline derivatives and pharmaceutical preparations
NZ197420A (en) * 1980-07-01 1984-04-27 Ici Australia Ltd -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives
JPS57123184A (en) 1980-12-16 1982-07-31 Hoffmann La Roche Novel manufacture of imidazoquinazolinone derivative
US4455311A (en) * 1981-08-28 1984-06-19 Hoffmann-La Roche Inc. Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system
ZA826088B (en) 1981-08-28 1983-04-27 Hoffmann La Roche Novel imidazoquinazoline derivatives
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
US5684153A (en) * 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
US4783467A (en) * 1985-06-05 1988-11-08 Pfizer Inc. Tetrahydroimidazoquinazolinone inotropic agents
GB8514207D0 (en) 1985-06-05 1985-07-10 Pfizer Ltd Cardiac stimulants
US4761416A (en) * 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
US4739056A (en) * 1986-11-26 1988-04-19 Syntex (U.S.A.) Inc. N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
JPH0730046B2 (ja) 1987-02-10 1995-04-05 第一製薬株式会社 キナゾリン酢酸誘導体
JP2544939B2 (ja) 1987-09-01 1996-10-16 大塚製薬株式会社 ベンゾヘテロ環誘導体
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
NZ234186A (en) 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
WO1991019810A1 (en) * 1990-06-15 1991-12-26 California Biotechnology Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
JPH04112255A (ja) 1990-09-03 1992-04-14 Casio Comput Co Ltd ターミナル識別データ設定方式
JP3510244B2 (ja) * 1991-01-21 2004-03-22 エラン ファーマシューティカルス，インコーポレイテッド アルツハイマー病に関するテストおよびモデル
US5672805A (en) * 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
AU2765992A (en) * 1991-10-03 1993-05-03 Indiana University Foundation Method for screening for alzheimer's disease
WO1993014200A1 (en) * 1992-01-07 1993-07-22 Tsi Corporation Transgenic animal models for alzheimer's disease
SE511886C2 (sv) * 1992-01-31 1999-12-13 Svedala Arbra Ab Sätt att styra en gyratorisk kross
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
CA2174429C (en) * 1993-10-27 2011-08-30 Lisa C. Mcconlogue Transgenic animals harboring app allele having swedish mutation
JPH07132033A (ja) * 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JPH10504964A (ja) * 1994-09-01 1998-05-19 メルク エンド カンパニー インコーポレーテッド 家族性型ヒトアミロイド前駆タンパク質を発現するトランスジェニック動物
JPH08151377A (ja) 1994-11-25 1996-06-11 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
ATE253051T1 (de) * 1999-01-22 2003-11-15 Kirin Brewery Chinolinderivate und chinazolinderivate
BR0015718A (pt) 1999-11-22 2002-07-23 Warner Lambert Co Quinazolinas e seu uso para inibição de enzimas de cinase dependente de ciclina
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US20040087548A1 (en) * 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1395257A1 (en) 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
EP1490065B1 (en) * 2002-03-22 2007-06-13 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
WO2004058686A1 (en) 2002-04-30 2004-07-15 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer’s disease
DE10301105B4 (de) 2003-01-09 2005-11-24 Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh Verwendung von 2-Amino-2H-chinazolin-Derivaten zur Behandlung von myeloproliferativen Erkrankungen, Bluthochdruck und Bronchodilation
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
US7294642B2 (en) * 2002-09-06 2007-11-13 Elan Pharmaceuticals, Inc. 1,3-Diamino-2-hydroxypropane pro-drug derivatives
EP1407774A1 (en) 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
CN1826334A (zh) 2003-03-18 2006-08-30 麦克公司 趋化因子受体活性的四氢吡喃基环戊基杂环酰胺调节剂
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
GB0325830D0 (en) 2003-11-05 2003-12-10 Novartis Ag Organic compounds
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
US8426429B2 (en) * 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
JP5046932B2 (ja) 2004-08-06 2012-10-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ β−セクレターゼ（ＢＡＣＥ）のインヒビターとして有用な新規の２−アミノ−キナゾリン誘導体
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
PT1789398E (pt) 2004-08-06 2010-10-21 Janssen Pharmaceutica Nv Derivados de 2-amino- quinazolina úteis como inibidores de β-secretase (bace)
US8383637B2 (en) * 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US20060074105A1 (en) * 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
CA2594946A1 (en) 2005-01-19 2006-07-27 Merck & Co., Inc Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
BRPI0611707A2 (pt) 2005-06-29 2012-04-24 Compumedics Ltd conjunto de sensor com ponte condutiva
ES2360957T3 (es) * 2005-10-25 2011-06-10 Janssen Pharmaceutica Nv Derivados de 2-amino-3,4-dihidro-pirido(3,4-d)-pirimidina utiles como inhibidores de la beta-secretasa (bace).
WO2007092839A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
US7776882B2 (en) * 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7868022B2 (en) * 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
BRPI0906625A2 (pt) * 2008-01-28 2015-07-14 Janssen Pharmaceutica Nv Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
AU2009209147B2 (en) * 2008-01-29 2013-03-14 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (BACE)

Also Published As

Publication number Publication date
PT1776349E (pt) 2010-12-06
EP1776349B1 (en) 2010-10-06
HRP20100595T1 (hr) 2010-12-31
WO2006017836A3 (en) 2006-06-29
DK1776349T3 (da) 2011-01-24
PL1776349T3 (pl) 2011-04-29
CN101035771A (zh) 2007-09-12
JP4884387B2 (ja) 2012-02-29
WO2006017836A2 (en) 2006-02-16
EP1776349A2 (en) 2007-04-25
ATE483692T1 (de) 2010-10-15
RS51630B (en) 2011-08-31
CY1111086T1 (el) 2015-06-11
ES2351667T3 (es) 2011-02-09
US20060178383A1 (en) 2006-08-10
US8436006B2 (en) 2013-05-07
JP2008509165A (ja) 2008-03-27
DE602005024004D1 (de) 2010-11-18

Similar Documents

Publication Publication Date Title
PL1776349T3 (pl) Pochodne 2-amino-chinazoliny użyteczne jako inhibitory beta-sekretazy (BACE)
PL1789398T3 (pl) Pochodne 2-amino-chinazoliny użyteczne jako inhibitory ß-sekretazy (BACE)
PT1966198E (pt) Derivados de 2-amino-3,4-di-hidro-pirido[3,4-d]pirimidina ?teis como inibidores de beta-secretase (bace)
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2007092846A3 (en) 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007092854A3 (en) 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007092839A3 (en) Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
WO2007019080A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease